MiRNA-124 induces neuroprotection and functional improvement after focal cerebral ischemia

Somayyeh Hamzei Taj1, Widuri Kho1, Adrien Riou2

  • 1In-vivo-NMR Laboratory, Max Planck Institute for Metabolism Research, Cologne, Germany.

Biomaterials
|April 1, 2016
PubMed

Insights

MicroRNA-124 (miR-124) therapy promotes neuroprotection and functional recovery after ischemic stroke by shifting microglia and macrophages to an anti-inflammatory M2 phenotype, reducing brain lesion size and increasing neuronal survival.

Area of Science:

  • Neuroscience
  • Molecular Biology
  • Regenerative Medicine

Background:

  • MicroRNA-124 (miR-124) is abundant in the CNS and influences microglial and macrophage polarization.
  • Pro-inflammatory M1 microglia/macrophages worsen secondary injury after ischemic stroke.
  • Shifting to an anti-inflammatory M2 phenotype is a neuroprotective strategy for stroke.

Purpose of the Study:

  • To investigate the therapeutic potential of miR-124 in a mouse model of ischemic stroke.
  • To determine if miR-124 can modulate microglial/macrophage polarization and promote neuroprotection.

Main Methods:

  • Transient middle cerebral artery occlusion (MCAO) was induced in C57BL/6 mice.
  • Liposomated miR-124 was administered at 48 hours and 10 days post-MCAO.
  • Immunohistochemistry for Arg-1 (M2 marker), Iba-1 (microglia/macrophages), NeuN (neurons), and GFAP (astrocytes) was performed.

Main Results:

  • Early miR-124 injection significantly increased neuronal survival and M2-polarized microglia/macrophages.
  • The lesion core size was significantly reduced over time with early miR-124 treatment.
  • Arg-1+ microglia/macrophages correlated with neuronal protection and functional recovery.

Conclusions:

  • miR-124 demonstrates neuroprotective and anti-inflammatory effects in ischemic stroke.
  • Early miR-124 treatment promotes beneficial M2 polarization and reduces lesion size.
  • miR-124 represents a promising therapeutic strategy for stroke recovery.

Related Concept Videos